BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23805888)

  • 1. Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma.
    Arakawa N; Miyagi E; Nomura A; Morita E; Ino Y; Ohtake N; Miyagi Y; Hirahara F; Hirano H
    J Proteome Res; 2013 Oct; 12(10):4340-50. PubMed ID: 23805888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
    Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
    PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
    Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
    Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
    Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
    Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
    Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
    Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary.
    Miyagi E; Arakawa N; Sakamaki K; Yokota NR; Yamanaka T; Yamada Y; Yamaguchi S; Nagao S; Hirashima Y; Kasamatsu Y; Kato H; Mogami T; Miyagi Y; Kobayashi H
    Int J Clin Oncol; 2021 Jul; 26(7):1336-1344. PubMed ID: 34009487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer.
    Wang B; Yu L; Yang GZ; Luo X; Huang L
    Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.
    Carbotti G; Orengo AM; Mezzanzanica D; Bagnoli M; Brizzolara A; Emionite L; Puppo A; Centurioni MG; Bruzzone M; Marroni P; Rossello A; Canevari S; Ferrini S; Fabbi M
    Int J Cancer; 2013 Jun; 132(11):2597-605. PubMed ID: 23169448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum glycome profiling: a biomarker for diagnosis of ovarian cancer.
    Biskup K; Braicu EI; Sehouli J; Fotopoulou C; Tauber R; Berger M; Blanchard V
    J Proteome Res; 2013 Sep; 12(9):4056-63. PubMed ID: 23889230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.
    Zou L; He X; Zhang JW
    Braz J Med Biol Res; 2010 Dec; 43(12):1232-8. PubMed ID: 21103788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A
    Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
    Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.
    Yuan L; Wan J; Huang C; Liang J; Liu M; Yue C; Li L
    Cancer Biomark; 2017 Dec; 21(1):97-104. PubMed ID: 29036787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LyGDI is a promising biomarker for ovarian cancer.
    Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
    Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.